Pharmacokinetics of interferon-β and the biological markers it induces

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 77-94

  Witt, Patricia L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007183256     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (54)

1. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis II: MRI analysis results. Neurology 1993; 43:662-667.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing- remitting multiple sclerosis I: Clinical results. Neurology 1993; 43: 655-661.
3. Jacobs L, Salazar AM, Herndon R, Reese P, Freeman A, Josefowics R, Cuetter A, Husain F, Smith WA, Ekes R, O'Malley JA. Multicentre double lind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986; 20:1411-1413.
4. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-13ser in healthy volunteers and its effects on serum neopterin. Pharm Res 1993; 10:567-572.
5. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon betaserine. J Natl Cancer Inst 1989; 81:1061-1068.
6. Chiang J, Gloff CA, Soike KF, Williams G. Pharmacokinetics and antiviral activity of recombinant human interferon-pser17 in African green monkeys. J Interferon Res 1993; 13:111-120.
7. Grunberg SM, Kempf RA, Venturi CL, Mitchell MS. Phase I study of recombinant beta-interferon given by four-hour infusion. Cancer Res 1987; 47: 1174-1178.
8. Abdi EA, Kamitomo VJ, McPherson TA, Konrad MW, Inoue M, Tan YH. Extended phase I study of human 13-interferon in human cancer. Clin Invest Med 1986; 9:33-40.
9. Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA. A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol 1982; 9:97-102.
10. Dhingra K, Duvic M, Hymes S, McLaughlin P, Rothberg J, Gutterman JU. A phase-I clinical study of low-dose oral interferon-a. J Immunother 1993; 14:51-55.
11. Maluish AE, Reid JW, Crisp EA, Overton WR, Levy H, Foon KA, Herberman RB. Immunomodulatory effects of poly(I, C)-LC in cancer patients. J Biol Response Mod 1985; 4:656-663.
12. Quesada JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte interferon (Clone A) in an intermittent schedule in cancer patients. J Natl Cancer Inst 1983; 70:1041-1046.
13. Liberati AM, Horisberger MA, Palmisano L, Astolfi S, Nastari A, Mechati S, Villa A, Mancini S, Arzano S, Grignani F. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-f3. J Interferon Res 1992; 12:329-336.
14. 13a. Billiau A, DeSomer P, Edy VG, DeClercq E, Heremans H. Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrobial Agents Chemother 1979; 16:56-63.
15. Kinney P, Triozzi P, Young D, Drago J, Behrens B, Wise H, Rinehart JJ. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. J Clin Oncol 1990; 8:881-885.
16. Witt PL, Storer BE, Bryan GT, Brown RR, Flashner M, Larocca AT, Colby CB, Borden EC. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-p. J Immunother 1993; 13:191-200.
17. Liberati AM, Fizzotti M, Proietti MG, DiMarzio R, Schippa M, Biscottini B, Senatore M, Berruto P, Canali S, Peretti G, Zanolo G. Biochemical host response to interferon-beta. J Interferon Res 1988; 8:765-777.
18. Jacobs L, Munschauer F. Treatment of multiple sclerosis with interferons. In: Rudick FA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London: Springer-Verlag, 1992: 233-250.
19. Rinehart JJ, Young D, Laforge J, Colborn D, Neidhart JA. Phase I/II trial of interferon beta-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res 1987; 47:2481-2487.
20. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH. Immunomodulatory and immunotherapeutic properties of recombinant gammainterferon and recombinant tumor necrosis factor in mice. Cancer Res 1987; 47:2563-2570.
21. Spear GT, Paulnock DM, Jordan RL, Meltzer DM, Merritt JA, Borden EC. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol 1987; 69:107-115.
22. Borden EC, Rinehart JJ, Storer BE, Trump DL, Paulnock DM, Teitelbaum AP. Biological and clinical effects of interferon betaser at two doses. J Interferon Res 1990; 10:559-570.
23. Hirayama K, Matsushita S, Kikuchi I, Iuchi M, Ohta N, Sasazuki T. HLADQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans. Nature 1987; 327:426-430.
24. Borden EC, Hawkins MJ, Sielaff KM, Storer BM, Schiesel JD, Smalley RB. Clinical and biological effects of recombinant interferon beta administered intravenously daily in a phase I trial. J Interferon Res 1988; 8:357-366.
25. Liberati AM, Garofani P, DeAngelis V, DiClemente F, Horisberger M, Cecchini M, Betti AR, Palmisano L, Astofi S, Nastari A, Villa A, Arzano S. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinantinterferon-beta given intravenously. J Interferon Res 1994; 14:61-69.
26. Fierlbeck G, Schreiner T. Incidence and clinical significance of therapyinduced neutralizing antibodies against interferon-β. J Interferon Res 1994; 14:205-206.
27. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214:1026-1028.
28. Wills RJ, Smith RA. Pharmacokinetics of interferons. In: Smith RA, ed. Interferon Treatment of Neurologic Disorders. New York: Marcel Dekker, 1988:103-134.
29. Hovanessian AG, Marcovistz R, Riviere Y, Guillon J-C, Tsiang H. Production and action of interferon in rabies virus infection. In: Smith RA, ed. Interferon Treatment of Neurologic Disorders. New York: Marcel Dekker, 1988:157-208.
30. Billiau A. Interferon therapy: pharmacokinetic and pharmacological aspects. Arch Virol 1981; 67:121-133.
31. Schafer TW, Lieberman M, Cohen M, Came PE. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972; 76:1326-1327.
32. Cummins JM, Tompkins MB, Olsen RG, Tompkins WA, Lewis MG. Oral use of human alpha interferon in cats. J Biol Response Mod 1988; 7:513-523.
33. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant A interferon following IV infusion and bolus, IM and PO administration to African green monkeys. J Interferon Res 1984; 4:399-409.
34. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985; 5:403-408.
35. Koech DK, Obel AO, Minowada J, Hutchinson VA, Cummins JM. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol Biother 1990; 2:91-95.
36. Hutchinson V, Cummins JM. Low-dose oral interferon in patient with AIDS. Lancet 1987; 2:1530-1531.
37. Koren S, Fleischmann WRJ. Orally administered interferons suppress bone marrow function. Proc Soc Exp Biol Med 1993; 204:155-164.
38. Witt PL, Goldstein D, Storer BE, Grossberg SE, Flashner M, Colby CB, Borden EC. Absence of biologic effects of orally administered interferonf3ser. J Interferon Res 1992; 12:411-413.
39. Schiller JH, Witt PL. Levamisole: clinical and biological effects. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer Updates. vol. 2. Philadelphia, Lippincott, 1992:1-14.
40. Halme M, Maasilta P, Mattson K, Cantell K. Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer. Respiration 1994; 61:105-107.
41. Freund M, VonWussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Diecher H, Poliwoda H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependence of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72:350-356.
42. Steis RG, Smith JWII, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL. Resistance to recombinant interferon alfa-2a in hairycell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318:1409-1413.
43. vonWussow P, Pralle H, Hochkeppel H-K, Jakschies D, Sonnen S, Schmidt H, Muller-Rosenau D, Franke M, Haferlach T, Zwingers T, Rapp U, Deicher H. Effective natural interferon-a therapy in recombinant interferon-a-resistant patients with hairy cell leukemia. Blood 1991; 78:38-43.
44. Steis RG, Smith JWII, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH. Loss of interferon antibodies during prolonged continuous interferon-a2a therapy in hairy cell leukemia. Blood 1991; 77: 792-798.
45. Konrad MW, Childs AL, Merigan TC, Borden EC. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol 1987; 7:365-375.
46. Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Vill E, Burg G. Formation of neutralizing antibodies against natural interferon-beta but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 1991; 67: 2300-2304.
47. Aulitzky WE, Peschel C, Despres D, Aman J, Trautman P, Tilg H, Rudolf G, Huttmann H, Obermeier J, Herold M, Huber C. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Ann Hematol 1993; 67: 205-211.
48. The IFNO Multiple Sclerosis Study Group. Beta interferon lb in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 1995; 45:1277-1285.
49. Ransohoff RM, Devajyothi C, Estes ML, Babcock G, Rudick RA, Frohman EM, Barna BP. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991; 33:103-112.
50. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 1985; 135:1857-1861.
51. Naito Y, Baba T, Suzuki H, Ayeno K. The antagonistic effect of interferon- β on the interferon-y-induced expression of HLA-DR antigen in a squamous cell carcinoma line. J Exp Pathol 1992; 6:75-87.
52. Inaba K, Kitaura M, Kato T, Watanabe Y, Kawade Y, Muramatsu S. Contrasting effect of alpha/beta and gamma interferons on expression of macrophage Ia antigens. J Exp Med 1986; 163:1030-1035.
53. Scotlandi K, Baldini N, Campanacci M, Lollini PL, Picci P, Serra M. Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factora. Anticancer Res 1992; 12:767-772.
54. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC. Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993; 13: 333-340.